🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Neoadjuvant bladder cancer data #ASCO24 for toripalimab & disitimab vedotin in muscle invasive bladder cancer (n=47). pCR⬆️63%. 14% G3/4 AEs. All surgeries occurred. 6 cycles of treatment. The 1st MMAE/IO neoadjuvant combo data look ☑️☑️. Randomised trials needed.

Bladder cancer highlight #ASCO24 Disitimab Vedotin with toripalimab show pCR rate >60% with no surgery cancelled due to AEs. Immature 1yr DFS >80% despite 60% T3 or more. The data are good enough for R3 studies. Although 6 more mos of follow up would be reassuring.

NICHE-2 published in NEJM —what an elegant work from super star Myriam Chalabi and senior John Haanen ! Study presented #ESMO22 and started the hashtag #ChalabiPlot => near 100% pathologic response in dMMR colon cancer! OncoAlert

Ecstatic and proud to share the NICHE-2 results, now published in NEJM. Out of 111 pts, 95% had an MPR , and 68% a pCR after only 4 weeks of #neoadjuvant #immunotherapy. Grateful to the pts and colleagues who made this possible. John Haanen nej.md/3Ku4X0H

⚡️NOW IN PRESS: Durable Objective Response to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation: A Molecular-Directed Strategy🧬 #PrecisionOncology 👉GU ASCO #GU24: Original multi-institutional series on off-label use of lurbi in SCBC-enriched GU cohorts Omar Alhalabi, MD

Tweetorial ascopubs.org/doi/pdf/10.120… 1/ #CaboNivo & #CaboNivoIpi have shown promising efficacy and safety in patients with metastatic urothelial carcinoma #mUC, metastatic renal cell carcinoma #mRCC & rare #GU tumors in a dose-escalation phase I study ascopubs.org/doi/full/10.12…

UroToday interview discussing our meta-analysis on dMMR and MSI-H in urothelial carcinoma Andrea Apolo, M.D. Giovanni Maria Iannantuono. Thanks for having me Sam S. Chang MD, MBA UroToday.com urotoday.com/video-lectures…

A 50-year-old woman presented with painless progressive thumb abduction weakness and atrophy of the hand, selectively involving the thenar muscles. #NeurologyRF 🧵

It was so much fun to chat with Joshua Hurwitz and Michael Fernando about dMMR and MSI-H in urothelial cancer on the Oncology for the Inquisitive Mind podcast. Thanks guys!

The #POUT Trial: Final results of adjuvant chemotherapy in #UTUC. 💙alison birtle joins Sam S. Chang MD, MBA highlighting the trial's significance, emphasizing the involvement of patients and their families > bit.ly/4cbw6Bb Rosemere Cancer Foundation NHS Lancashire Teaching Hospitals CC Vanderbilt Urology

The Apolo Lab. Love working with this bunch Andrea Apolo, M.D. Nicholas Simon Dr. Andre R. Kydd Salah Boudjadi, M.D, Ph.D.

📺 #WatchNow Sam S. Chang MD, MBA Vanderbilt Urology interviews Elias Chandran, MBBS National Cancer Institute on a systematic review and meta-analysis of mismatch repair deficiency (dMMR) and microsatellite instability in #UrothelialCarcinoma > bit.ly/4cOPeFl

A great advice on #Personalstatement from a Program Director Keep drafting. #Match2025 #MedTwitter Inside The Match Project IMG ™

📺 #WatchNow Sam S. Chang MD, MBA Vanderbilt Urology interviews Elias Chandran, MBBS National Cancer Institute on a systematic review and meta-analysis of mismatch repair deficiency (dMMR) and microsatellite instability in #UrothelialCarcinoma > bit.ly/4cOPeFl

Happy holidays from the NCI #BladderCancer Research Team! NCI CCR GU Malignancies @NCICCR_MOS @NCICCR_UroOnc National Cancer Institute

We have several accruing #ClinicalTrials for patients with #SmallCell #BladderCancer 1. #Lurbi +/- #Avelumab LASER clinicaltrials.gov/study/NCT06228… 2. #SG +/- #Atezo SMART clinicaltrials.gov/study/NCT06161… 3. #CaboNivoIpi ICONIC clinicaltrials.gov/study/NCT03866… [email protected] / ☎️240-760-6006